NCT02375464View on ClinicalTrials.gov

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Gallium-68 DOTATOC

Imaging with Gallium-68 DOTATOC

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER

NCT02375464 - Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter